Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology

被引:21
作者
Allen, C
Jiang, K
Malbecq, W
Goadsby, PJ
机构
[1] Merck & Co Inc, Whitehous Stn, Raritan, NJ 08869 USA
[2] Merck & Co Inc, W Point, PA USA
[3] Merck Sharp & Dohme Europe Inc, Brussels, Belgium
[4] Inst Neurol, London WC1N 3BG, England
关键词
D O I
10.1046/j.1468-2982.1999.019006552.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Survival analysis, or, more generally, time-to-event analysis, is of interest when the data represent the time to a defined event. While well established in oncology, it has not been widely applied to migraine research, possibly because the data are usually collected intermittently, rather than continuously, and because of the awkwardness of interpreting treatment effect in survival terms. However, it represents an interesting approach for the analysis of time-to-headache relief, which addresses the clinically relevant question of who gets better sooner. The analysis uses data from all time-points to define the likelihood of headache relief following treatment throughout the entire assessment period. These data can then be used to quantify and test the difference between two therapies.
引用
收藏
页码:552 / 556
页数:5
相关论文
共 12 条
[1]  
*CDER, 1992, GUID CLIN EV AN DRUG
[2]  
Collett D., 1994, MODELLING SURVIVAL D, P237
[3]  
EDWARDS C, 1991, EUR NEUROL, V31, P300
[4]  
KALBFLEISHJD, 1980, STAT ANAL FAILURE TI
[5]  
KIRKHAM AJT, 1991, EUR NEUROL, V31, P314
[6]   DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS REQUIRING PROLONGED OBSERVATION OF EACH PATIENT .2. ANALYSIS AND EXAMPLES [J].
PETO, R ;
PIKE, MC ;
ARMITAGE, P ;
BRESLOW, NE ;
COX, DR ;
HOWARD, SV ;
MANTEL, N ;
MCPHERSON, K ;
PETO, J ;
SMITH, PG .
BRITISH JOURNAL OF CANCER, 1977, 35 (01) :1-39
[7]   METHODOLOGY OF CLINICAL-TRIALS OF SUMATRIPTAN IN MIGRAINE AND CLUSTER HEADACHE [J].
PILGRIM, AJ .
EUROPEAN NEUROLOGY, 1991, 31 (05) :295-299
[8]   REGRESSION-ANALYSIS OF GROUPED SURVIVAL DATA WITH APPLICATION TO BREAST-CANCER DATA [J].
PRENTICE, RL ;
GLOECKLER, LA .
BIOMETRICS, 1978, 34 (01) :57-67
[9]   Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine [J].
Solomon, GD ;
Cady, RK ;
Klapper, JA ;
Earl, NL ;
Saper, JR ;
Ramadan, NM .
NEUROLOGY, 1997, 49 (05) :1219-1225
[10]   GUIDELINES FOR CONTROLLED TRIALS OF DRUGS IN MIGRAINE .1. EDITION [J].
TFELTHANSEN, P .
CEPHALALGIA, 1991, 11 (01) :1-12